Bdenza
✅ Slows cancer progression
✅ Reduces tumor growth
✅ Improves survival outcomes
✅ Supports prostate treatment
✅ Enhances quality of life
Bdenza conține Enzalutamide 40 mg.
✓ Verificat medical de Morgan Ellis — Cercetător farmaceutic · 8 ani de experiență · Ultima recenzie: mai 2026
⚡ Quick Answer — What is Bdenza?
Bdenza is an oral tablet from Beacon Pharmaceuticals containing enzalutamide 40 mg — a second-generation androgen-receptor signalling inhibitor. Used for metastatic castration-resistant prostate cancer (mCRPC), non-metastatic CRPC și metastatic hormone-sensitive prostate cancer. Standard dose: 160 mg once daily (4 × 40 mg tablets), with or without food. More potent than first-generation anti-androgens (bicalutamide, flutamide) and active in castration-resistant disease where they fail. Seizure risk — avoid in patients with history of seizures. Other key risks: hypertension, fatigue, falls/fractures, cognitive effects, posterior reversible encephalopathy syndrome (rare). Continue concurrent LHRH agonist throughout treatment. Mandatory monitoring: BP at baseline + at each visit, periodic LFTs + FBC.
📦 Fiecare comandă este acoperită de politica noastră de Politica noastră de Reexpediere Garantată — dacă coletul dumneavoastră nu sosește în 20 de zile lucrătoare, îl relivrăm.
What Is Bdenza?
Bdenza is an oral tablet from Beacon Pharmaceuticals containing enzalutamide 40 mg. Enzalutamide is a second-generation androgen-receptor (AR) signalling inhibitor — mechanistically distinct from the first-generation anti-androgens (bicalutamide, flutamide). It is licensed for: metastatic castration-resistant prostate cancer (mCRPC) in chemotherapy-naïve and post-docetaxel patients; non-metastatic CRPC with rapidly rising PSA; and metastatic castration-sensitive prostate cancer (mHSPC) with concurrent ADT.
How Does Bdenza Work?
Enzalutamide is a triple-action AR signalling inhibitor:
- Competitive AR binding with much higher affinity than first-generation anti-androgens.
- Inhibits AR nuclear translocation — even when bound by androgen, prevents the receptor from entering the nucleus.
- Inhibits AR-DNA binding — even if AR enters the nucleus, prevents binding to androgen-response elements on target genes.
This triple mechanism makes enzalutamide active in castration-resistant prostate cancer, where AR overexpression and AR-splice variants make first-generation anti-androgens ineffective.
Utilizări și indicații
- Metastatic castration-resistant prostate cancer (mCRPC) — chemotherapy-naïve (PREVAIL) and post-docetaxel (AFFIRM)
- Non-metastatic CRPC with PSA doubling time < 10 months (PROSPER)
- Metastatic hormone-sensitive prostate cancer (mHSPC) with ADT (ARCHES, ENZAMET)
Bdenza Dosage and How to Take
Doza standard: 160 mg once daily (4 × 40 mg tablets) at the same time each day, with or without food.
- Swallow tablets whole with water. Do NOT chew, dissolve or split.
- Continue concurrent LHRH agonist therapy throughout enzalutamide treatment unless surgically castrated.
- Mandatory monitoring: blood pressure at baseline and each clinic visit; LFTs and FBC periodically; PSA every 3 months.
- Falls and fracture prevention: elderly patients have increased fall and fracture risk on enzalutamide. Bone health assessment, calcium + vitamin D, consider bisphosphonate.
- Dose modifications for moderate hepatic impairment, severe adverse events, or grade ≥ 3 toxicity: reduce to 80 or 120 mg/day under specialist guidance.
- Do not stop without oncologist instruction.
Side Effects of Bdenza
Frecvente: fatigue (the dominant side effect), hot flushes, hypertension, fall and fracture risk (elderly), arthralgia, headache, dizziness, decreased weight, anxiety, insomnia.
Important:
- Seizures (< 1% in trials) — lower seizure threshold; avoid in any patient with seizure history or on drugs lowering seizure threshold
- Cognitive effects: memory difficulties, concentration impairment
- Hypertension — new-onset or worsening; treat aggressively
- Posterior reversible encephalopathy syndrome (PRES) — rare but documented; new-onset severe headache, confusion, vision changes, seizures
- Hepatotoxicity (mild LFT rises common; severe rare)
- Neutropenia, anaemia
Avertismente și precauții
- Seizure history (any type): avoid enzalutamide. If essential, specialist neurology + oncology supervision.
- Drugs that lower seizure threshold (bupropion, clozapine, tramadol, fluoroquinolones, theophylline): caution.
- Falls and fracture risk: bone health assessment, supportive care.
- Hypertension: baseline + ongoing BP monitoring.
- Severe hepatic impairment (Child-Pugh C): not recommended.
- PRES symptoms: new severe headache, vision change, confusion — stop and seek same-day review.
- Pregnancy / fertility: male-only indication. Use condom + contraception with female partners of childbearing potential during treatment + 3 months after.
Interacțiuni medicamentoase
| Combinați cu | Efect | Ce să faceți |
|---|---|---|
| Strong CYP2C8 inhibitors (gemfibrozil) | Raise enzalutamide levels — toxicity risk | Reduce enzalutamide to 80 mg/day if combination unavoidable. |
| Strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St John's wort) | Lower enzalutamide levels — treatment failure | Avoid. If unavoidable, increase to 240 mg/day under specialist guidance. |
| Warfarin and other CYP2C9 / CYP3A4 substrates with narrow therapeutic index | Enzalutamide is a strong CYP3A4 inducer — lowers many drug levels | Switch warfarin to a DOAC (apixaban, edoxaban) or monitor INR weekly. |
| Drugs lowering seizure threshold (bupropion, tramadol, clozapine, fluoroquinolones, theophylline) | Increased seizure risk | Avoid where possible. |
| LHRH agonists (goserelin, leuprorelin) | Standard background therapy | Continue throughout enzalutamide treatment. |
Depozitare
- Store at room temperature, 15–30°C.
- Keep out of reach of children, women of childbearing potential, and pets.
Alternative conexe pe MedsBase
Other oncology medications stocked alongside this product:
Browse all anti-cancer medications →
De ce să comanzi de la MedsBase
Fiecare lot este procurat de la un producător certificat WHO-GMP. Comenzile sunt expediate în ambalaje simple, fără marcă, de la partenerii noștri de onorare și acoperite de Politica noastră de Reexpediere Garantată: dacă un colet nu ajunge în 20 de zile lucrătoare, trimitem gratuit o nouă comandă, fără întrebări.
Related Anti-Cancer Medications
Other oncology medications stocked alongside this product:
- Bicalumutide (bicalutamide 50 mg)
- Cytomid (flutamide 250 mg)
- Endace (megestrol 40/160 mg)
- Tamilong (tamoxifen 10/20 mg)
- Votrient (pazopanib 200/400 mg)
Întrebări frecvente
How is Bdenza different from bicalutamide or flutamide?
Enzalutamide is a second-generation AR signalling inhibitor with three mechanisms (AR binding + AR nuclear translocation block + AR-DNA binding block) versus the single mechanism of first-generation drugs. The clinical implication: enzalutamide works in castration-resistant disease where bicalutamide and flutamide have failed. It is also more potent and produces deeper PSA responses but with more cognitive side effects, hypertension and fall risk.
Why is seizure history a contraindication?
Enzalutamide crosses the blood-brain barrier and lowers seizure threshold. In trials, seizure incidence was < 1% but increased in patients with predisposing factors. Avoid enzalutamide in any patient with prior seizure (any type), brain metastases, or concurrent drugs lowering seizure threshold (bupropion, tramadol, clozapine, fluoroquinolones, theophylline). If enzalutamide is essential in such a patient, neurology and oncology specialists must agree on the risk-benefit.
Will I have to stop ADT (LHRH agonist) when I start Bdenza?
No — continue your LHRH agonist (goserelin, leuprorelin, etc.) throughout enzalutamide treatment. The combination of background castration + AR signalling inhibition is essential. Stopping the LHRH agonist allows testosterone to recover, which can defeat enzalutamide's effect.
Why is fatigue so common on Bdenza?
Fatigue is the most common and clinically significant side effect — affecting around 35% of patients in trials. The cause is multifactorial: profound androgen deprivation, possible direct CNS effects, anaemia. Manage with structured exercise (counterintuitively effective), good sleep hygiene, screening and treatment of anaemia, and consideration of dose reduction (160 → 120 mg/day) if intolerable.
What is PRES and how do I recognise it?
Posterior reversible encephalopathy syndrome (PRES) is a rare but documented enzalutamide complication characterised by severe headache, confusion, visual changes (cortical blindness), seizures and altered consciousness. Stop enzalutamide immediately and seek same-day medical review for any of these symptoms. Most cases resolve with drug discontinuation but timely recognition prevents permanent neurological injury.
Are there many drug interactions I need to worry about?
Yes — enzalutamide is a strong CYP3A4 inducer and lowers blood levels of many co-prescribed drugs. The most clinically important: warfarin (switch to a DOAC or check INR weekly), direct oral anticoagulants (specialist review), some statins, some antihypertensives, opioids, some antiepileptics. Tell every doctor you are on enzalutamide.
Can I drive on Bdenza?
Caution — fatigue, dizziness and (rarely) seizures may impair driving. Most patients adapt and drive safely after the first few weeks. Avoid driving or operating machinery if you experience significant fatigue, dizziness, or any cognitive symptoms.
Bdenza vs abiraterone — which is better?
Both are second-line options after first-generation anti-androgen failure. Head-to-head data is limited; choice depends on side-effect preference and comorbidities. Enzalutamide: more fatigue, cognitive effects, hypertension, fall risk; no steroid co-prescription needed. Abiraterone: requires concurrent prednisone 5 mg twice daily; more hypertension and fluid retention; may worsen diabetes control. Discuss with your oncologist.
More options in Anti Cancer Medication
Clasificate în funcție de volumul recent de comenzi MedsBase — ce aleg alți clienți în această categorie.
| Concentrație | 40 mg |
|---|---|
| Cantitate | 28 Capsules, 56 Capsules, 84 Capsules, 112 Capsules |
Bdenza
Întrebări și răspunsuri
Bdenza
Produse similare
Recenzii
Nu există recenzii încă